Assessment of the adverse reactions of Gadobenate Dimeglumine (Gd-BOPTA) from preliminary clinical experience in Taiwan

Chin Ming Jeng, Shu Ching Tai, Young Chen Wang, Ching Huei Kung, Wen Yu Lee, Chan Ming Yang, Hsio Yun Chang, Chau Ying Wu, Yung Chien Huang, Yu Jen Wang

Research output: Contribution to journalArticle

Abstract

Gd-BOPTA (MultiHance®) is a gadolinium-based contrast agent that was approved in Taiwan in March, 2004. It was supplied as sterile, clear, colorless solution with the concentration of 0.5M in a ready-for-use form. We conducted this study to evaluate the safety profile of this particular gadolinium chelate in 1041 patients referred for contrast-enhanced MRI studies in our hospital between October 2004 and February 2005. Of these cases, 188 females and 214 males aged between 22-96 years (mean, 57.5 years) without fasting were injected with hand-push single bolus injection (2 mL/second) of a dosage of 0.2ml/kg body weight (0.1 mmol/kg). The other 323 females and 316 males aged between 21-94 years (mean, 58.6 years) with 4 hours fasting were injected by slow injection (10 mL/minute). A total of 16 (1.54%) cases experienced adverse reactions (ARs) considered to have definite relationship to Gd-BOPTA. All ARs were graded as mild and each of the patients recovered fully without sequelae. No definite serious Gd-BOPTA-related ARs occurred in our cases. There is no significant difference of the incidences of ARs including nausea, vomiting, skin rash, dizziness and chillness between these two groups. There were completely no ARs in all 9 cases older than 91 years. Our results confirm Gd-BOPTA (Gadobenate Dimeglumine, MultiHance) is a safe contrast agent for routine MRI studies in clinical patients. Our experiences also showed that the incidence of its ARs is not significantly influenced by the injection rate and fasting status prior to injection of the agent.

Original languageEnglish
Pages (from-to)257-262
Number of pages6
JournalChinese Journal of Radiology
Volume30
Issue number5
Publication statusPublished - Oct 1 2005
Externally publishedYes

Fingerprint

Taiwan
Fasting
Injections
Gadolinium
Contrast Media
Incidence
Dizziness
gadobenic acid
Exanthema
Nausea
Vomiting
Hand
Body Weight
Safety

Keywords

  • Gadobenate dimeglumine
  • Gd-BOPTA
  • MR contrast media
  • MR imaging
  • Safety of MR contrast media

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Jeng, C. M., Tai, S. C., Wang, Y. C., Kung, C. H., Lee, W. Y., Yang, C. M., ... Wang, Y. J. (2005). Assessment of the adverse reactions of Gadobenate Dimeglumine (Gd-BOPTA) from preliminary clinical experience in Taiwan. Chinese Journal of Radiology, 30(5), 257-262.

Assessment of the adverse reactions of Gadobenate Dimeglumine (Gd-BOPTA) from preliminary clinical experience in Taiwan. / Jeng, Chin Ming; Tai, Shu Ching; Wang, Young Chen; Kung, Ching Huei; Lee, Wen Yu; Yang, Chan Ming; Chang, Hsio Yun; Wu, Chau Ying; Huang, Yung Chien; Wang, Yu Jen.

In: Chinese Journal of Radiology, Vol. 30, No. 5, 01.10.2005, p. 257-262.

Research output: Contribution to journalArticle

Jeng, CM, Tai, SC, Wang, YC, Kung, CH, Lee, WY, Yang, CM, Chang, HY, Wu, CY, Huang, YC & Wang, YJ 2005, 'Assessment of the adverse reactions of Gadobenate Dimeglumine (Gd-BOPTA) from preliminary clinical experience in Taiwan', Chinese Journal of Radiology, vol. 30, no. 5, pp. 257-262.
Jeng, Chin Ming ; Tai, Shu Ching ; Wang, Young Chen ; Kung, Ching Huei ; Lee, Wen Yu ; Yang, Chan Ming ; Chang, Hsio Yun ; Wu, Chau Ying ; Huang, Yung Chien ; Wang, Yu Jen. / Assessment of the adverse reactions of Gadobenate Dimeglumine (Gd-BOPTA) from preliminary clinical experience in Taiwan. In: Chinese Journal of Radiology. 2005 ; Vol. 30, No. 5. pp. 257-262.
@article{7d3d74e83a624f339952d04811267242,
title = "Assessment of the adverse reactions of Gadobenate Dimeglumine (Gd-BOPTA) from preliminary clinical experience in Taiwan",
abstract = "Gd-BOPTA (MultiHance{\circledR}) is a gadolinium-based contrast agent that was approved in Taiwan in March, 2004. It was supplied as sterile, clear, colorless solution with the concentration of 0.5M in a ready-for-use form. We conducted this study to evaluate the safety profile of this particular gadolinium chelate in 1041 patients referred for contrast-enhanced MRI studies in our hospital between October 2004 and February 2005. Of these cases, 188 females and 214 males aged between 22-96 years (mean, 57.5 years) without fasting were injected with hand-push single bolus injection (2 mL/second) of a dosage of 0.2ml/kg body weight (0.1 mmol/kg). The other 323 females and 316 males aged between 21-94 years (mean, 58.6 years) with 4 hours fasting were injected by slow injection (10 mL/minute). A total of 16 (1.54{\%}) cases experienced adverse reactions (ARs) considered to have definite relationship to Gd-BOPTA. All ARs were graded as mild and each of the patients recovered fully without sequelae. No definite serious Gd-BOPTA-related ARs occurred in our cases. There is no significant difference of the incidences of ARs including nausea, vomiting, skin rash, dizziness and chillness between these two groups. There were completely no ARs in all 9 cases older than 91 years. Our results confirm Gd-BOPTA (Gadobenate Dimeglumine, MultiHance) is a safe contrast agent for routine MRI studies in clinical patients. Our experiences also showed that the incidence of its ARs is not significantly influenced by the injection rate and fasting status prior to injection of the agent.",
keywords = "Gadobenate dimeglumine, Gd-BOPTA, MR contrast media, MR imaging, Safety of MR contrast media",
author = "Jeng, {Chin Ming} and Tai, {Shu Ching} and Wang, {Young Chen} and Kung, {Ching Huei} and Lee, {Wen Yu} and Yang, {Chan Ming} and Chang, {Hsio Yun} and Wu, {Chau Ying} and Huang, {Yung Chien} and Wang, {Yu Jen}",
year = "2005",
month = "10",
day = "1",
language = "English",
volume = "30",
pages = "257--262",
journal = "Chinese Journal of Radiology",
issn = "1018-8940",
publisher = "中華民國放射線醫學會",
number = "5",

}

TY - JOUR

T1 - Assessment of the adverse reactions of Gadobenate Dimeglumine (Gd-BOPTA) from preliminary clinical experience in Taiwan

AU - Jeng, Chin Ming

AU - Tai, Shu Ching

AU - Wang, Young Chen

AU - Kung, Ching Huei

AU - Lee, Wen Yu

AU - Yang, Chan Ming

AU - Chang, Hsio Yun

AU - Wu, Chau Ying

AU - Huang, Yung Chien

AU - Wang, Yu Jen

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Gd-BOPTA (MultiHance®) is a gadolinium-based contrast agent that was approved in Taiwan in March, 2004. It was supplied as sterile, clear, colorless solution with the concentration of 0.5M in a ready-for-use form. We conducted this study to evaluate the safety profile of this particular gadolinium chelate in 1041 patients referred for contrast-enhanced MRI studies in our hospital between October 2004 and February 2005. Of these cases, 188 females and 214 males aged between 22-96 years (mean, 57.5 years) without fasting were injected with hand-push single bolus injection (2 mL/second) of a dosage of 0.2ml/kg body weight (0.1 mmol/kg). The other 323 females and 316 males aged between 21-94 years (mean, 58.6 years) with 4 hours fasting were injected by slow injection (10 mL/minute). A total of 16 (1.54%) cases experienced adverse reactions (ARs) considered to have definite relationship to Gd-BOPTA. All ARs were graded as mild and each of the patients recovered fully without sequelae. No definite serious Gd-BOPTA-related ARs occurred in our cases. There is no significant difference of the incidences of ARs including nausea, vomiting, skin rash, dizziness and chillness between these two groups. There were completely no ARs in all 9 cases older than 91 years. Our results confirm Gd-BOPTA (Gadobenate Dimeglumine, MultiHance) is a safe contrast agent for routine MRI studies in clinical patients. Our experiences also showed that the incidence of its ARs is not significantly influenced by the injection rate and fasting status prior to injection of the agent.

AB - Gd-BOPTA (MultiHance®) is a gadolinium-based contrast agent that was approved in Taiwan in March, 2004. It was supplied as sterile, clear, colorless solution with the concentration of 0.5M in a ready-for-use form. We conducted this study to evaluate the safety profile of this particular gadolinium chelate in 1041 patients referred for contrast-enhanced MRI studies in our hospital between October 2004 and February 2005. Of these cases, 188 females and 214 males aged between 22-96 years (mean, 57.5 years) without fasting were injected with hand-push single bolus injection (2 mL/second) of a dosage of 0.2ml/kg body weight (0.1 mmol/kg). The other 323 females and 316 males aged between 21-94 years (mean, 58.6 years) with 4 hours fasting were injected by slow injection (10 mL/minute). A total of 16 (1.54%) cases experienced adverse reactions (ARs) considered to have definite relationship to Gd-BOPTA. All ARs were graded as mild and each of the patients recovered fully without sequelae. No definite serious Gd-BOPTA-related ARs occurred in our cases. There is no significant difference of the incidences of ARs including nausea, vomiting, skin rash, dizziness and chillness between these two groups. There were completely no ARs in all 9 cases older than 91 years. Our results confirm Gd-BOPTA (Gadobenate Dimeglumine, MultiHance) is a safe contrast agent for routine MRI studies in clinical patients. Our experiences also showed that the incidence of its ARs is not significantly influenced by the injection rate and fasting status prior to injection of the agent.

KW - Gadobenate dimeglumine

KW - Gd-BOPTA

KW - MR contrast media

KW - MR imaging

KW - Safety of MR contrast media

UR - http://www.scopus.com/inward/record.url?scp=31644441323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31644441323&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 257

EP - 262

JO - Chinese Journal of Radiology

JF - Chinese Journal of Radiology

SN - 1018-8940

IS - 5

ER -